Are you investing in biotech? IP can be a company’s best or worst asset. Here’s why.
IP tends to slip into the background during the due diligence phase. Overshadowed by flashy pitch decks and promising product pipelines. IP spans both scientific depth and legal nuance, directly affecting a biotech’s competitive edge. Overlooking these can lead to missed opportunities or underestimated risks.
The solution can be to bring in a patent attorney who truly understands the technology. By doing an IP portfolio review, you’ll gain insight into the real strengths and vulnerabilities. It’s a strategic step toward investing with confidence.
It's worth making sure IP gets the attention it deserves. After all, great science combined with strong patents can transform your investment.